ARS Pharma director granted 30,000 stock options
ARS Pharmaceuticals director Laura Shawver received a new stock option grant, not an open-market trade.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ARS Pharmaceuticals director Laura Shawver received a new stock option grant, not an open-market trade. The Form 4 shows an award of options to acquire 30,000 shares of common stock at an exercise price of $10.54 per share. Following this grant, she holds 30,000 stock options directly. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting, according to the footnote. The options expire on June 23, 2036, giving a long exercise window tied to her board service.
Insider Trade Summary
Grant/Award: 30,000 shares
Grant/Award
1 txn
Insider
Shawver Laura
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 30,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Key Figures
Options granted: 30,000 options
Exercise price: $10.54 per share
Underlying shares: 30,000 shares
+3 more
6 metrics
Options granted
30,000 options
Stock Option (right to buy) granted to director
Exercise price
$10.54 per share
Conversion or exercise price of options
Underlying shares
30,000 shares
Common stock underlying the options
Post-grant option holdings
30,000 options
Total options following this transaction
Vesting date trigger
June 24, 2027
Earlier of this date or 2027 annual meeting
Option expiration
June 23, 2036
Expiration date of the options
Key Terms
Stock Option (right to buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 10.5400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ARS Pharmaceuticals (SPRY) report for Laura Shawver?
ARS Pharmaceuticals reported a compensation-related grant to director Laura Shawver. She received stock options for 30,000 shares of common stock at a fixed exercise price, rather than buying or selling shares in the open market.
How many ARS Pharmaceuticals (SPRY) options did Laura Shawver receive and at what price?
Laura Shawver received stock options for 30,000 shares of ARS Pharmaceuticals common stock. The options carry an exercise price of $10.54 per share, setting the price she must pay if she chooses to exercise in the future.
When do Laura Shawver’s ARS Pharmaceuticals (SPRY) options vest?
The options vest in full on the earlier of June 24, 2027 or the date of ARS Pharmaceuticals’ 2027 annual meeting of stockholders. The exact meeting date will be set later by the company’s board of directors.
When do the stock options granted to Laura Shawver at ARS Pharmaceuticals (SPRY) expire?
The stock options granted to Laura Shawver expire on June 23, 2036. She can choose to exercise them any time after they vest and before this expiration date, subject to the company’s equity plan and option agreement terms.
Is Laura Shawver’s ARS Pharmaceuticals (SPRY) Form 4 a stock purchase or sale?
The Form 4 reflects a grant of stock options, not a purchase or sale of common shares. It is coded as an acquisition (A) for compensation, with no open-market buying or selling activity reported in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
